Improving tumor mutational burden calibration in non-European patients.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.1559
Abstract: 1559 Background: Tumor mutational burden (TMB), has been recently granted FDA approval as a biomarker for ICI treatment in tumors with a high mutation load (≥ 10/MB). To leverage this biomarker in the clinical setting,… read more here.
Keywords: non eur; eur pts; tmbh; tumor ... See more keywords